Post Marketing Surveillance of Roflumilast in Korea

Trial Profile

Post Marketing Surveillance of Roflumilast in Korea

Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors AstraZeneca; Takeda
  • Most Recent Events

    • 21 Jun 2017 Status changed from recruiting to completed.
    • 26 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top